KYKOF News and Press, Kyowa Hakko Kogyo From 08/06/21

Kyowa Kirin Co., Ltd. (OTCPK:KYKOF): Q2 GAAP EPS ¥46.65. Revenue of ¥165.02B (+4.6 Y/Y). Press Release For further details see: Kyowa Kirin reports Q2 results

The following slide deck was published by Kyowa Kirin Co., Ltd. in conjunction with their 2021 Q2 earnings call. For further details see: Kyowa Kirin Co., Ltd. 2021 Q2 - Results - Earnings Call Presentation

Early indications show that Kyowa Kirin has a blockbuster drug with KHK4083, a treatment for severe atopic dermatitis (eczema). Phase 2 trials have shown encouraging results and the agreement to jointly develop and commercialize the drug with Amgen is a positive signal. With both ...

Amgen (AMGN) and Kyowa Kirin (KYKOF) announced an agreement to jointly develop and commercialize KHK4083 an anti-OX40 fully human monoclonal antibody currently set for Phase 3 studies in atopic dermatitis with potential application in other autoimmune diseases.Per the terms, Amgen will m...

Kyowa Kirin (KYKOF) announced that the European Medicines Agency ((EMA)) has recommended the self-administration option of CRYSVITA (burosumab) for the treatment of X-linked hypophosphataemia ((XLH)).The decision by the Committee for Medicinal Products for Human Use ((CHMP)) of EMA ...

The Beer Tax Unification Act will damage Kirin's competitive pricing in the beer-substitute market for the medium to long term. Kirin's 53.8% stake in pharmaceutical company Kyowa Kirin causes problems over parent attributable net income and free cash flow disclosure. The shares a...

CERC-002, a monoclonal antibody (mAB) from Cerecor (CERC), reduced respiratory failure and death in a small trial of hospitalized COVID-19 patients.Results, published as a preprint in medRxiv and not yet peer reviewed, found that 83.9% of patients with acute respiratory distress syndrome give...

Cerecor's (CERC) wholly-owned subsidiary, Aevi Genomic Medicine (GNMX) has entered into an expanded agreement with Kyowa Kirin (KYKOF), for exclusive worldwide rights to develop, manufacture and commercialize CERC-002 monoclonal antibody for all indications. Under the terms of agreement, Kyow...

Twist Bioscience ([[TWST]] -0.4%) has signed a partnership agreement with Kyowa Kirin Pharmaceutical Research, a subsidiary of Kyowa Kirin ([[KYKOF]]) to discover novel antibodies for therapeutic use against an undisclosed G protein-coupled receptor ((GPCR)) target molecule.Under the ter...

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on a 2-product pipeline including SNDX-5613, a Menin inhibitor for MLLR/NPM1, and SNDX-6352, a monoclonal antibody for GVHD. Syndax has a pipeline of 3 therapeutics (SNDX-5613, SNDX-6352, Entinostat) with 2 s...